Cadrenal reports Q2 net loss $3.7M, cash $5.6M; plans tecarfarin trial in ESKD dialysis patients

Cadrenal Therapeutics, Inc.

2025-Q2 EPS reported -$3.95

Net loss of $3.7M for Q2 2025 versus $2.4M in Q2 2024; G&A increased to $2.7M from $1.2M.
Cash and equivalents $5.6M at June 30, 2025, down from $10.0M at December 31, 2024.
Plans to initiate clinical trial of tecarfarin in ESKD patients transitioning to dialysis; site activation expected later in 2025.
Completed technical transfer and cGMP manufacturing of tecarfarin drug substance at a U.S. CDMO site.
Added to Russell 3000E and Russell Microcap indexes effective June 30, 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.